Category: News & Events

Research Progress in Heart Rate Variability Applications in Exercise Rehabilitation for Cardiovascular Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart rate variability (HRV) is an important marker for assessing the balance of the autonomic nervous system and clinical prognosis, because it can be non-invasively and easily measured, and the results are accurate and valuable. HRV is widely applied in cardiovascular disease fields. Exercise training is an important part of cardiac rehabilitation. Personalized sports rehabilitation therapy can effectively prevent the emergence of cardiovascular diseases, decrease the risk of recurrent cardiovascular events, and ameliorate dysfunction, as well as limitations in life, work, and social participation, caused by adverse cardiovascular events. However, sports rehabilitation can have drawbacks, in that improper training can cause injury, excessive fatigue, or even harmful cardiovascular events. To support future applications, this article reviews recent applications of HRV in sports rehabilitation for cardiovascular diseases.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0071

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhaoxin Zhu, Jianying Shen and Yan Zhang et al. Research Progress in Heart Rate Variability Applications in Exercise Rehabilitation for Cardiovascular Diseases. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0071

Loading

Heart Failure Guideline Directed Medical Therapy: Which One and When?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Over the past several decades, major strides have been made in the management of heart failure with reduced ejection fraction (HFrEF). The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF. This guideline directed therapy (GDMT) includes renin angiotensin receptor (RAAS) blockade, preferentially with angiotensin receptor neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter inhibitors (SGLT2i). An optimal GDMT regimen has been estimated to achieve greater than 70% mortality benefit. Unfortunately, most patients with HFrEF are not taking the appropriate medications or doses. Several clinical challenges and questions arise when attempting to initiate and titrate these medications. Although the guidelines offer several suggestions for this process, each patient’s hemodynamic profile varies markedly, thus making development of a uniform algorithm difficult. As new trials are performed, greater emphasis is being placed on more aggressive titration of GDMT. Most importantly, initiation of GDMT should start during hospitalization and continue with close outpatient follow-up. Identifying each patient profile, defined by volume status, blood pressure, heart rate, and kidney function, dictates the order and timing of GDMT titration.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0077

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Michelle Dimza and Juan M. Aranda. Heart Failure Guideline Directed Medical Therapy: Which One and When?. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0077

Loading

Population-Based Clinical Studies Using Routinely Collected Data in Hong Kong, China: A Systematic Review of Trends and Established Local Practices

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Routinely collected health data are increasingly used in clinical research. No study has systematically reviewed the temporal trends in the number of publications and analyzed different aspects of local research practices and their variations in Hong Kong, China, with a specific focus on research ethics governance and approval.

PubMed was systematically searched from its inception to March 28, 2023, for studies using routinely collected healthcare data from Hong Kong.

A total of 454 studies were included. Between 2000 and 2009, 32 studies were identified. The number of publications increased from 5 to 120 between 2010 and 2022. Of the investigator-led studies using the Hospital Authority (HA)’s cross-cluster data (n = 393), 327 (83.2%) reported receiving ethics approval from a single cluster/university-based REC, whereas 50 studies (12.7%) did not report approval from a REC. For use of the HA Data Collaboration Lab, approval by a single hospital-based or University-based REC is accepted. Repeated submission of identical ethics applications to different RECs is estimated to cost HK$4.2 million yearly.

Most studies reported gaining approval from a single cluster REC before retrieval of cross-cluster HA data. Substantial cost savings would result if repeated review of identical ethics applications were not required.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0073

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Derek Wu, Ronald Nam and Keith Sai Kit Leung et al. Population-Based Clinical Studies Using Routinely Collected Data in Hong Kong, China: A Systematic Review of Trends and Established Local Practices. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0073

Loading

Long-term Effects of Nicorandil Combined with Dihydropyridine Calcium Channel Blockers on Cardiovascular Outcomes in Patients with Coronary Heart Disease: A Real-world Observational Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating whether the addition of nicorandil to a dihydropyridine calcium channel blocker (DHP-CCB) regimen might decrease the occurrence of major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD).

A multicenter, retrospective, real-world study was conducted. Between August 2002 and March 2020, 7413 eligible patients with CHD were divided into DHP-CCB plus nicorandil combination (n = 1843) and DHP-CCB (n = 5570) treatment groups. The primary outcome was MACE, defined as a composite of myocardial infarction, stroke, and all-cause mortality. Propensity score matching was used to adjust for confounding factors.

After propensity score matching, combination therapy, compared with DHP-CCBs alone, was associated with a lower risk of MACE (HR: 0.80, 95% CI: 0.67–0.97). The combination group also had a lower risk of stroke (HR: 0.55, 95% CI: 0.44–0.69), but not myocardial infarction (HR: 1.21, 95% CI: 0.91–1.61) or all-cause mortality (HR: 1.24, 95% CI: 0.63–2.44). Subgroup analysis revealed more prominent benefits of the combined treatment on MACE in patients with than without diabetes.

The combination of nicorandil and DHP-CCBs may be more beneficial than DHP-CCBs alone in decreasing long-term risks of MACE and stroke in patients with CHD.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0072

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jia Cheng, Zixuan Zhang and Hongyang Shu et al. Long-term Effects of Nicorandil Combined with Dihydropyridine Calcium Channel Blockers on Cardiovascular Outcomes in Patients with Coronary Heart Disease: A Real-world Observational Study. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0072

Loading

Clinical Relevance of Uric Tobacco-Specific Nitrosamine and Severe Abdominal Aortic Calcification in a National Survey of the United States

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This cross-sectional study is the first investigation of the relationships among uric tobacco-specific nitrosamine (TSNA), N′-nitrosonornicotine (NNN), and abdominal aortic calcification (AAC) in adults in the United States.

The final sample (2713 participants 40 years of age and older) was obtained from the National Health and Nutrition Examination Survey (NHANES) 2013–2014. The risk of severe AAC according to uric NNN, the dose–response relationship between uric NNN and severe AAC, and the threshold effect were analyzed with multivariate logistic regression models, a cubic spline model, and a two-piecewise linear regression model, respectively.

In the fully adjusted model, the odds ratio (and 95% confidence interval) of severe AAC for participants in the high uric NNN group with respect to the low uric NNN group was 2.39 (1.59–3.61) (P < 0.001). After adjustment for multiple covariates, the risk of severe AAC increased 1.515-fold for every 1 ng/dL increase in uric NNN when the concentration of uric NNN was below 1.354 ng/dL. The association between uric NNN and severe AAC was stable among various subgroups.

In a sample of United States civilians, uric NNN levels positively correlated with the risk of severe AAC.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0075

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Fang Wang and Jingang Zheng. Clinical Relevance of Uric Tobacco-Specific Nitrosamine and Severe Abdominal Aortic Calcification in a National Survey of the United States. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0075

Loading

Associations Among Microvascular Dysfunction, Fatty Acid Metabolism, and Diabetes

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from impaired insulin secretion or insulin resistance. Diabetes poses a major global health concern, because of its increasing prevalence and substantial morbidity and mortality. This review explores the relationships between altered fatty acid metabolism and microcirculatory impairments in diabetes. Dysregulation of fatty acid metabolism in diabetes leads to changes in fatty acid profiles, abnormal lipid accumulation, and increased oxidative stress. These changes contribute to microvascular dysfunction through mechanisms such as endothelial dysfunction, impaired nitric oxide availability, inflammation, and oxidative damage. Understanding this intricate interplay is essential for identifying novel therapeutic strategies to alleviate vascular complications in diabetes. By targeting specific pathways involved in fatty acid metabolism and microvascular dysfunction, interventions can be developed to improve patient outcomes. This article is aimed at contributing to future research and the development of effective strategies for preventing and managing diabetes-associated microcirculatory impairments, to ultimately enhance the quality of life for people living with diabetes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0076

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jianjun Wu, Youqi Zhang and Liu Ji et al. Associations Among Microvascular Dysfunction, Fatty Acid Metabolism, and Diabetes. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0076

Loading

Access to Cardiac Rehabilitation: Hurdles and Hopes for Improvement

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Consistent evidence gathered over many years supports the benefits of cardiac rehabilitation, including decreases in mortality and hospitalizations, and increase in quality of life. In one study of 601,099 Medicare patients older than 65 years with coronary disease, 5-year mortality was lower in patients who participated in cardiac rehabilitation than those who did not (16.3% versus 24.6%, respectively, P < 0.0001). Another study has shown significantly fewer hospitalizations for heart failure among patients who participated in cardiac rehabilitation than those who did not: the patients who underwent cardiac rehabilitation had 11 admissions for a total of 41 hospitalized days over a 24 week period, whereas those who did not had 33 admissions for a total of 187 hospitalized days (P < 0.001). The clinical benefits of cardiac rehabilitation, as documented in both young and older participants, include increased exercise capacity, energy and total quality of life.

Although cardiac rehabilitation is a class 1 indication for patients who have sustained acute coronary syndrome as well as those with heart failure, it is grossly underused. In one study, only 24.4% of a cohort of 366,103 Medicare patients with a qualifying diagnosis for cardiac rehabilitation assessed from 2016 to 2017 participated in cardiac rehabilitation. Of those who participated, only 26.9% completed the program. A closer evaluation of the barriers preventing referral, enrolment and completion of cardiac rehabilitation is needed to better understand the limitations and to promote solutions to these problems.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0074

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Natalie J. Bracewell and Ellen C. Keeley. Access to Cardiac Rehabilitation: Hurdles and Hopes for Improvement. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0074

Loading

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy is a multifaceted complication of diabetes that lacks effective treatments. Berberine (BBR), a bioactive compound from Rhizoma coptidis, has potential therapeutic implications, but its precise role in diabetic cardiomyopathy remains to be defined.

In this study, a diabetic cardiomyopathy model was established by administration of a high-fat diet and streptozotocin injection to C57BL/6J mice. Concurrently, the mice received BBR treatment daily for a duration of 8 weeks. After the treatment period, myocardial injury, cardiac function, and the levels of oxidative stress and apoptosis were assessed.

BBR significantly ameliorated cardiac dysfunction and histopathological damage caused by diabetic cardiomyopathy. This treatment also elevated serum superoxide dismutase levels while decreasing malondialdehyde levels. The anti-apoptotic activity of BBR was evidenced by a decrease in TUNEL-positive cells and the percentage of apoptotic cells, as determined by flow cytometry, in conjunction with diminished levels of BCL2-associated X protein/B cell lymphoma 2 (BAX/BCL2) in heart tissues. Mechanistically, BBR was found to ameliorate diabetic cardiomyopathy by upregulating the expression of myocardial methionine sulfoxide reductase A (MsrA) and concurrently suppressing cardiac CaMKII oxidation.

BBR alleviates diabetic cardiomyopathy by inhibiting myocardial apoptosis and oxidative stress through the MsrA and CaMKII signaling pathways.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0064

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xiaoqiang Sun, Zhuqing Li and Li Wang et al. Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0064

Loading

Correlation between the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Left Ventricular Hypertrophy in Older Patients with Hypertension

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Hypertension and left ventricular hypertrophy (LVH) have emerged as significant risk factors for cardiovascular events and all-cause mortality. Inflammation and nutrition play critical roles in the development of hypertension and damage to target organs. The HALP Score, which assesses levels of hemoglobin, albumin, lymphocytes, and platelets, is an index closely associated with inflammation and nutrition, and has been demonstrated to be particularly effective in the older population. Hence, the objective of this study was to examine the correlation between the HALP Score and LVH in older patients with hypertension.

Data from 234 older patients, including clinical data, were collected and retrospectively analyzed and also routine blood, liver function, kidney function, and cardiac ultrasound parameters. All patients were categorized into a non-left ventricular hypertrophy (NLVH) group (n = 131) or an LVH group (n = 103). The association between the HALP Score and LVH was investigated, and potential influencing factors were considered.

The LVH group had a significantly lower HALP Score than the NLVH group. Logistic regression analysis revealed that a lower HALP Score and female sex were independent factors associated with LVH in older patients with hypertension (OR = 0.944, 9.962, 95% CI: 0.910–0.979, 3.866–24.300, P = 0.002, <0.001). The area under the curve for the HALP Score in diagnosing LVH in older patients with hypertension was 0.708 (95% CI: 0.641–0.776, P = 0.002).

The HALP Score is significantly associated with LVH in older patients with hypertension: lower scores indicate a greater likelihood of LVH. The HALP Score has moderate diagnostic value for LVH in this population.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0068

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yingfang Liu, Yan Wang and Ye Meng et al. Correlation between the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Left Ventricular Hypertrophy in Older Patients with Hypertension*. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0068

Loading

Left Bundle Branch Ablation Guided by a Three-Dimensional Mapping System: A Novel Method for Establishing a Heart Failure Animal Model

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Few studies have been conducted to establish animal models of left bundle branch block by using three-dimensional mapping systems. This research reported by this article was aimed at creating a canine left bundle branch block model by using a three-dimensional mapping system.

A three-dimensional mapping system was used to map and ablate the left bundle branch in beagles. Ten canines underwent radiofrequency ablation, among which left bundle branch block was successfully established in eight, one experienced ventricular fibrillation, and one developed third-degree atrioventricular block. The maximum HV interval measured within the left ventricle was 29.00 ± 2.93 ms, and the LBP-V interval at the ablation site was 20.63 ± 2.77 ms. The LBP-V interval at the ablation target was 71.08% of the maximum HV interval.

This three-dimensional mapping system is a reliable and effective guide for ablation of the left bundle branch in dogs.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0066

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Pengkang He, Han Jin and Yiran Hu et al. Left Bundle Branch Ablation Guided by a Three-Dimensional Mapping System: A Novel Method for Establishing a Heart Failure Animal Model. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0066

Loading